Scholarlink

Abstract <p>Tumor vaccines represent a promising strategy for mobilizing the immune system against malignancies, however, their efficacy is limited by poor antigen immunogenicity, inefficient lymph nodes (LNs) accumulation, and inadequate antigen presentation by antigen-presenting cells (APCs), particularly dendritic cells (DCs). Pyroptosis, a pro-inflammatory form of cell death known to enhance immunogenicity, and autophagy, a cellular pathway that promotes MHC class I and II antigen presentation in APCs, have emerged as two compelling mechanisms to address these limitations. Here, we developed a biomimetic hybrid nanovaccine (hDMVac) by repeatedly extruding pyroptotic B16 and DC2.4, followed by loading with beclin-1. The results show that hDMVac exhibited a particle size of approximately 160&#xa0;nm and showed enhanced accumulation in LNs after subcutaneous injection, with time-dependent distribution within the lymphatic system. The incorporation of pyroptotic tumor cells significantly enhanced antigen immunogenicity. Moreover, beclin-1 loading robustly induced autophagy in DCs, facilitating DCs maturation and markedly enhancing cross-presentation of antigens within LNs. The synergistic effect significantly amplified antigen-specific T cell activation. Consequently, hDMVac effectively suppressed tumor growth in both prophylactic and therapeutic melanoma models. This dual strategy represents a synergistic approach to overcoming the limitations of conventional tumor vaccines, representing a clinically translatable platform compatible with existing immunotherapies for improved tumor treatment.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Autophagy-enhanced hybrid pyroptotic vesicles as personalized vaccines for cancer immunotherapy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月8日

查看全文
  • Han Yan,
  • Ling Wu,
  • Jun Liu,
  • Ruyi Wang,
  • Jiaye Lu,
  • Fengze Miao,
  • Ying Li,
  • Quangang Zhu,
  • Zongguang Tai,
  • Zhongjian Chen

摘要

Abstract

Tumor vaccines represent a promising strategy for mobilizing the immune system against malignancies, however, their efficacy is limited by poor antigen immunogenicity, inefficient lymph nodes (LNs) accumulation, and inadequate antigen presentation by antigen-presenting cells (APCs), particularly dendritic cells (DCs). Pyroptosis, a pro-inflammatory form of cell death known to enhance immunogenicity, and autophagy, a cellular pathway that promotes MHC class I and II antigen presentation in APCs, have emerged as two compelling mechanisms to address these limitations. Here, we developed a biomimetic hybrid nanovaccine (hDMVac) by repeatedly extruding pyroptotic B16 and DC2.4, followed by loading with beclin-1. The results show that hDMVac exhibited a particle size of approximately 160 nm and showed enhanced accumulation in LNs after subcutaneous injection, with time-dependent distribution within the lymphatic system. The incorporation of pyroptotic tumor cells significantly enhanced antigen immunogenicity. Moreover, beclin-1 loading robustly induced autophagy in DCs, facilitating DCs maturation and markedly enhancing cross-presentation of antigens within LNs. The synergistic effect significantly amplified antigen-specific T cell activation. Consequently, hDMVac effectively suppressed tumor growth in both prophylactic and therapeutic melanoma models. This dual strategy represents a synergistic approach to overcoming the limitations of conventional tumor vaccines, representing a clinically translatable platform compatible with existing immunotherapies for improved tumor treatment.

Graphical abstract